Basic Alysena Information

• INN (International Nonproprietary Name): Levonorgestrel and Ethinyl Estradiol
• Brand Names Available In Canada (English): Alesse, Aviane, Altavera, and other equivalents
• ATC Code: G03AA07
• Forms & Dosages: Oral tablets; typical strength 0.1 mg levonorgestrel + 0.02 mg ethinyl estradiol per active tablet; available as Alesse 21 (21 active) and Alesse 28 (21 active + 7 placebo)
• Manufacturers In Canada (English): Pfizer Canada Inc.; generic suppliers include Apotex, Teva, Sandoz
• Registration Status In Canada (English): Approved Prescription Drug (Rx); regulated in Health Canada’s Drug Product Database
• OTC / Rx Classification: Prescription Only (Rx)

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

Recent evidence from 2022 to 2025 continues to support low‑dose levonorgestrel plus ethinyl estradiol combined oral contraceptives as effective options for contraception.

There were no large randomized controlled trials exclusive to Alesse or Alysena initiated in Canada during that period.

The strongest data come from international meta‑analyses and large pharmacoepidemiologic cohorts comparing low‑dose combined oral contraceptives with higher‑estrogen agents.

These pooled studies examined outcomes such as contraceptive effectiveness, cycle control, and adverse events including venous thromboembolism.

Canadian post‑market surveillance and Health Canada vigilance reports showed findings consistent with international data and no new, product‑specific safety signals for Alesse/Alysena formulations between 2022 and 2025.

Main Outcomes

Effectiveness remains very high with perfect use, exceeding 99% efficacy for contraception when taken correctly.

Typical‑use effectiveness is lower and depends on adherence to daily dosing.

Low‑dose regimens consistently report good cycle control and reductions in menstrual blood loss for many users.

Comparative analyses show fewer estrogen‑related adverse effects with 20 μg ethinyl estradiol regimens versus older higher‑dose pills.

Safety Observations

Pooled analyses confirm the known small elevation in venous thromboembolism risk with combined hormonal contraceptives.

Risk magnitude is lower with 20 μg ethinyl estradiol regimens compared with higher‑dose estrogen products.

Clinical guidance emphasises individual risk assessment — including age, smoking, BMI, and thrombophilia status — prior to prescribing.

Health Canada post‑market reports mirrored international findings and did not identify novel safety issues specific to these brands in 2022–2025.

Clinical Mechanism Of Action

Layman’s Explanation

Alesse and Alysena contain two hormones: levonorgestrel (a progestin) and ethinyl estradiol (an oestrogen).

Together, they mainly prevent pregnancy by stopping ovulation.

They also thicken cervical mucus to make it harder for sperm to reach the egg.

Additionally, they change the uterine lining so implantation is less likely.

Scientific Breakdown

Ethinyl estradiol reduces follicle‑stimulating hormone (FSH) pulse amplitude, helping to suppress follicular development.

Levonorgestrel helps suppress the luteinizing hormone (LH) surge that triggers ovulation and exerts progestogenic effects on cervical mucus and endometrium.

Pharmacodynamics

Daily dosing maintains negative feedback on the hypothalamic–pituitary–ovarian axis to prevent follicular maturation and ovulation.

Pharmacokinetics

Ethinyl estradiol is orally bioavailable and undergoes hepatic first‑pass metabolism.

Levonorgestrel has high oral bioavailability, binds plasma proteins, and is metabolized in the liver.

Clinically important interactions include agents that induce hepatic enzymes, especially CYP3A4 inducers, which can lower steroid levels and reduce contraceptive efficacy.

The ATC classification G03AA07 reflects its status as a systemic hormonal contraceptive.

Common dosing formats include Alesse 21 and Alesse 28 blister packs containing 0.1 mg levonorgestrel + 0.02 mg ethinyl estradiol per active tablet.

Scope Of Approved And Off-Label Use

Health Canada Approvals (DIN-based)

Health Canada approves levonorgestrel plus ethinyl estradiol combinations as prescription‑only combined oral contraceptives.

Products are assigned a DIN and appear in the Drug Product Database.

Packaging commonly includes Alesse 21 and Alesse 28 formats with 21 active tablets and 7 placebo tablets for the 28‑day packs.

The approved indication is contraception; these products are not approved for emergency contraception.

Notable Off-Label Trends In Canadian Practice

Clinicians commonly prescribe low‑dose combined oral contraceptives off‑label for menstrual regulation, dysmenorrhea, acne, and menorrhagia.

Extended or continuous use (skipping placebo weeks) for menstrual suppression is also practised and documented in primary care and university clinics.

Adolescents post‑menarche typically receive standard adult dosing with attention to contraindication screening.

Off‑label use should balance benefits against absolute risks such as VTE and hepatic contraindications and be documented in the clinical record.

Dosage Strategy

General Dosing Per Health Canada Monographs

Standard dosing is one active tablet orally once daily for 21 days followed by seven days placebo for 28‑day packs.

For 21‑tablet packs, take one active tablet daily for 21 days then no tablets for seven days before starting the next pack.

Tablet strength commonly available in Canada is 0.1 mg levonorgestrel + 0.02 mg ethinyl estradiol per active tablet.

Missed‑dose guidance: if one active tablet is missed, take it as soon as remembered, even if that means two tablets in one day.

Condition‑Specific Dosing Adjustments

For two or more missed active tablets, take the most recent missed tablet ASAP, discard other missed tablets, and use backup contraception for seven days.

Adolescents use standard adult dosing after menarche.

These products are not indicated for post‑menopausal women and are inappropriate for women over about 50 years of age.

Severe hepatic impairment is a contraindication; caution is advised in mild–moderate hepatic or renal impairment.

Enzyme inducers such as certain anticonvulsants may necessitate alternative contraception or additional barrier methods, and bariatric or malabsorption states may favour non‑oral methods.

Annual risk reassessment is recommended or sooner if new risk factors arise.

Safety Protocols

Contraindications (Canadian Advisories)

Absolute contraindications include active thromboembolic disease, history of stroke or coronary artery disease, migraines with aura, and current breast cancer.

Uncontrolled hypertension, diabetes with vascular complications, severe liver disease, and known hypersensitivity to ingredients are also absolute contraindications.

Relative contraindications include obesity (BMI >30), smoking heavily (especially age >35), hyperlipidemia, gallbladder disease, and chronic renal impairment.

Adverse Effects (Post‑Market Reports)

Common adverse effects reported include nausea, breast tenderness, headache, and irregular spotting; these are usually transient.

Post‑market surveillance documents mood changes, menstrual disturbances, and rare serious events such as VTE and hepatic dysfunction.

Clinicians should perform baseline assessments including blood pressure and thrombotic risk history and counsel patients about red‑flag symptoms such as unilateral leg pain, sudden breathlessness, and sudden severe headaches.

Documenting informed consent and discussing alternatives is standard practice under Canadian clinical guidance.

Interaction Mapping

Food Interactions Common In Canadian Diet

There are no clinically significant food interactions that alter efficacy for Alesse or Alysena tablets.

Normal meals, coffee, and dairy do not affect contraceptive effectiveness in routine use.

Severe vomiting or diarrhoea can impair oral absorption and triggers missed‑pill and backup contraception protocols.

Drug Combinations Flagged By Health Canada

Clinically important interactions are mainly hepatic enzyme‑mediated.

Potent CYP3A4 inducers such as rifampin, rifabutin, carbamazepine, phenobarbital, and some antiretrovirals can reduce steroid levels and contraceptive effectiveness.

St John’s wort also lowers effectiveness and should be avoided in users of combined oral contraceptives.

Most common antibiotics do not interact significantly, with rifamycins flagged as primary offenders.

Reviewing prescription, OTC, and herbal products is essential and advise barrier backup when interacting agents are used.

Patient Experience Analysis

Canadian Survey Data

Canadian surveys and community pharmacy feedback indicate high satisfaction with low‑dose levonorgestrel/ethinyl estradiol pills for cycle control and tolerability.

Short‑term side effects such as early‑cycle spotting, transient nausea, and mood variability are commonly reported and often resolve within months.

Many patients switch brands or formulations if side effects persist, with generics frequently substituted in community practice.

Forum & Community Pharmacy Trends

Online searches often use brand terms like Alesse, Alysena, and Alesse generic when seeking availability and cost information.

Pharmacists in major chains report dispensing generics such as Aviane or Altavera when brand Alesse is unavailable and providing counselling on missed‑dose rules and interactions.

Adolescents and university clinics often discuss pack preferences, with some choosing 28 packs for predictable placebo days and others preferring 21 packs for convenience.

Distribution & Pricing Landscape

National Pharmacy Chains

Alesse, Alysena and generic equivalents are distributed through major Canadian chains including Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs.

Prescriptions and DIN‑listed products are required for dispensing in standard practice.

Community and chain pharmacists commonly handle substitutions and patient counselling when brand supplies are limited.

Online Pharmacy Availability & Provincial Restrictions

Online pharmacies and telemedicine platforms increasingly offer same‑day or mail delivery options, subject to provincial regulations on pharmacist prescribing and renewals.

Provincial drug plans such as Ontario Drug Benefit, BC PharmaCare, and RAMQ may cover COCs for eligible groups, and coverage rules differ by age and income.

In our online pharmacy, alysena is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross-Border US Comparisons

Generic options can be cheaper in the United States, but cross‑border purchasing must consider regulatory differences, prescription rules, and safety assurances.

Brand discontinuations can shift demand to generics, and pharmacists play a key role in safe substitution and patient education.

Alternative Options

Comparison Of DIN‑Approved Alternatives

Alternatives include other low‑dose combined oral contraceptives such as Yaz, Yasmin, Microgynon, and Marvelon.

Progestin‑only pills, implants, intrauterine devices, and injectables are effective alternatives, each with different risk profiles and adherence considerations.

Long‑acting reversible contraception (LARC) like IUDs and implants offer high effectiveness and reduce user‑dependence.

Pros And Cons Checklist

• Pros: Well‑studied low‑dose formulation, good tolerability, predictable cycles, available in 21/28 pack formats.
• Cons: Requires daily dosing, small increased VTE risk compared with non‑combined methods, susceptible to interactions with enzyme inducers.
• Progestin‑only and LARC options are preferable for smokers over 35, those with migraine with aura, or people with thrombotic risk factors.

Regulatory Status

Health Canada Approval Process

Levonorgestrel plus ethinyl estradiol products are prescription only and are authorised through Health Canada’s review of safety, efficacy and quality.

Approved product monographs outline indications, contraindications, dosing and adverse events.

Manufacturers must maintain post‑market vigilance and report adverse events to Health Canada.

DIN And Bilingual Labelling Rules

Products carry a DIN for specific brand/generic formulations and must meet bilingual labelling requirements for sale across Canada.

Provincial formularies may list specific DINs for coverage and substitution rules should be followed by prescribers and pharmacists.

Consolidated FAQ

Q1: Is Alesse/Alysena available over the counter in Canada?

A: No — these products are prescription only; consult a prescriber or pharmacist for access and alternatives.

Q2: Can I use Alesse/Alysena if I smoke?

A: Smoking increases cardiovascular risk; combined COCs are contraindicated in women over 35 who smoke heavily (>15 cigarettes/day); an individual risk assessment is required.

Q3: What if I miss two pills?

A: Take the most recent missed tablet as soon as remembered, discard other missed tablets, continue and use barrier/back‑up contraception for seven days; follow the product monograph for detailed steps.

Q4: Are generics equivalent?

A: Generic levonorgestrel/ethinyl estradiol products such as Aviane and Altavera are bioequivalent and commonly dispensed; check the DIN and discuss with your pharmacist.

Q5: Does provincial drug coverage apply?

A: Coverage varies by province and program; ask your pharmacist about Ontario Drug Benefit, BC PharmaCare, RAMQ eligibility and low‑cost generic options.

Visual Guide

Suggested infographic elements include a 28‑day blister diagram showing 21 active tablets and seven placebo days with a missed‑pill flowchart for quick patient reference.

Include a contraindication checklist with clear red flags such as a history of VTE, migraine with aura, active cancer, uncontrolled hypertension, and severe liver disease.

A provincial coverage map with icons for Ontario Drug Benefit, BC PharmaCare and RAMQ can guide patients to coverage resources.

Display common purchase channels including major pharmacy logos and telemedicine badges and add a note to verify the DIN when receiving substituted brands.

Interaction strips should list common CYP3A4 inducers and advise when barrier backup is needed.

Storage & Transport

Canadian Household Guidelines

Store Alesse and Alysena tablets at controlled room temperature, 15–30°C (59–86°F).

Keep tablets in the original blister to protect them from moisture and light and avoid bathroom storage where humidity fluctuates.

Do not leave packs in vehicles during Canadian seasonal extremes where temperatures may exceed recommended ranges.

Cold-Chain Storage Where Applicable

No cold‑chain is required and tablets should not be frozen.

For mail‑order or pharmacy delivery, packaging should protect products from heat and moisture; pharmacies commonly use insulated shipping during summer months when heat is a concern.

Dispose of expired or unwanted tablets through pharmacy take‑back programs rather than household waste.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Pharmacists should perform medication reconciliation, verify DIN and brand/generic equivalence, and screen for contraindications such as smoking status and history of VTE.

Counselling should cover adherence strategies like taking the pill at the same time daily, missed‑pill rules, and drug interactions including CYP3A4 inducers.

Provide written bilingual information and document counselling in the patient file.

Provincial Health Authority Guidance

Follow provincial protocols for pharmacist prescribing and renewals; some provinces allow pharmacist‑initiated contraception renewals and emergency dispensing — check Ontario, BC, and Quebec rules.

Reassess risk annually or when new risk factors develop and provide a bridging strategy when switching formulations to maintain contraceptive protection.

Delivery Across Canada (English)

Storage, Transport And Emergency Handling

Keep tablets out of reach of children and check expiry dates before use.

In case of suspected overdose, management is supportive; symptoms may include nausea, vomiting, and withdrawal bleeding.

Return expired or unused tablets to a pharmacy take‑back program for safe disposal.

Final Notes From The Pharmacist

If switching brands because of cost or supply, expect some transient spotting or side effects and use a safe bridging plan if required.

When in doubt about interactions or contraindications, consult a pharmacist to review your full medication and health history.

Generics such as Aviane and Altavera are bioequivalent and commonly substituted when brand Alesse is not available.

Always follow the product monograph instructions for missed pills and store tablets at 15–30°C to preserve effectiveness.